Find Oncology Drugs in Phase I Clinical Development

Lead Product(s): EOS-850

Therapeutic Area: Oncology

Highest Development Status: Phase I Product Type: Undisclosed

Partner/Sponsor/Collaborator: Minister of Economy and Research

Deal Size: $16.4 million Upfront Cash: Undisclosed

Deal Type: Funding January 30, 2020

Details:

Funds will be used to progress iTeos’ two highly innovative clinical-stage oncology programs: a best-in class A2A receptor antagonist and an ADCC-enabled anti-TIGIT antibody drug candidate

Lead Product(s): GMI-1359

Therapeutic Area: Oncology

Highest Development Status: Phase I Product Type: Small molecule

Partner/Sponsor/Collaborator: Not Applicable

Deal Size: Not Applicable Upfront Cash: Not Applicable

Deal Type: Not Applicable January 30, 2020

Details:

Proof-of-concept Phase 1b trial evaluating safety and biomarkers of anti-cancer effect in patients with hormone receptor positive metastatic breast cancer.

Lead Product(s): BI 1701963

Therapeutic Area: Oncology

Highest Development Status: Phase I Product Type: Undisclosed

Partner/Sponsor/Collaborator: Not Applicable

Deal Size: Not Applicable Upfront Cash: Not Applicable

Deal Type: Not Applicable January 30, 2020

Details:

Boehringer Ingelheim initiates Phase 1 trial for a FORMA-discovered, BI-licensed protein-protein interaction program and BMS initiates Phase 1B trial for FORMA-discovered, Celgene-licensed pan BET inhibitor.

Lead Product(s): Aldoxorubicin

Therapeutic Area: Oncology

Highest Development Status: Phase I Product Type: Small molecule

Partner/Sponsor/Collaborator: ImmunityBio

Deal Size: $343.0 million Upfront Cash: Undisclosed

Deal Type: Agreement January 29, 2020

Details:

CytRx out-licensed global development, manufacturing, and commercialization rights for aldoxorubicin to ImmunityBio Inc. in July 2017.

Lead Product(s): ACTR707,Trastuzumab

Therapeutic Area: Oncology

Highest Development Status: Phase I Product Type: Large molecule

Partner/Sponsor/Collaborator: Not Applicable

Deal Size: Not Applicable Upfront Cash: Not Applicable

Deal Type: Not Applicable January 29, 2020

Details:

Cohort 1 recruitment is complete with no dose-limiting toxicity reported in the ATTCK-34-01 Phase 1 trial testing Unum's novel ACTR707 antibody-coupled T cell receptor investigational therapy with trastuzumab.

Lead Product(s): SY-5609,Fulvestrant

Therapeutic Area: Oncology

Highest Development Status: Phase I Product Type: Small molecule

Partner/Sponsor/Collaborator: Not Applicable

Deal Size: Not Applicable Upfront Cash: Not Applicable

Deal Type: Not Applicable January 28, 2020

Details:

SY-5609 has shown substantial anti-tumor activity, including complete regressions, in multiple preclinical models of solid tumors, at doses below the maximum tolerated dose (MTD).

Lead Product(s): IK-175

Therapeutic Area: Oncology

Highest Development Status: Phase I Product Type: Small molecule

Partner/Sponsor/Collaborator: Not Applicable

Deal Size: Not Applicable Upfront Cash: Not Applicable

Deal Type: Not Applicable January 28, 2020

Details:

The launch of the first-in-human clinical study within three years of the beginning of the research program underscores the rapid progress IK-175 in Patients with Advanced Solid Tumors.

Lead Product(s): TILT-123

Therapeutic Area: Oncology

Highest Development Status: Phase I Product Type: Large molecule

Partner/Sponsor/Collaborator: Biotheus

Deal Size: Undisclosed Upfront Cash: Undisclosed

Deal Type: Licensing Agreement January 27, 2020

Details:

Under the agreement TILT has granted Biotheus rights for development and commercialization of TILT’s proprietary oncolytic virus TILT-123 in Greater China.

Lead Product(s): Ficlatuzumab,Paclitaxel,Gemcitabine

Therapeutic Area: Oncology